Precision-First Therapeutics: Building the Next Roche with Diego Rey, Co-Founder and CSO of Endpoint Health

We discuss Diego's career from building GeneWeave (acquired by Roche) to Endpoint Health now. Endpoint is pioneering a new business model merging diagnostics, data, and drug development to start with patient data and back into a therapy. The company is using their platform to develop first-line medicines for indications in infectious diseases with no approved therapies and beyond. Truly, Endpoint is leading a new wave of progress within critical and chronic illnesses. A favorite quote of mine after speaking with Diego: during an acquisition, "as an entrepreneur, you do a deal like this once." so while at GeneWeave they hired a bank to organize the entire process.